Robert Gut, M.D., Ph.D., is the Chief Medical Officer, heading clinical, medical and regulatory affairs globally for Versartis, Inc. an endocrine-focused biopharmaceutical company
Dr. Gut has nearly 20 years of experience in the biopharmaceutical industry leading clinical development and medical affairs activities in hematology and other therapeutic areas. For the majority of his career, Dr. Gut served as Vice President, Clinical Development & Medical Affairs at Novo Nordisk Inc., where he headed the company’s U.S. Biopharm Medical organization with leading products in hemophilia, endocrinology and women’s health (NovoSeven®, Norditropin® and Vagifem®), totaling approximately $1.6 billion in U.S. revenue. Over past years, Dr. Gut’s contributions have helped achieve six FDA product approvals and three new product indications. Dr. Gut has supported the launch of nine new products, overseeing medical activities including medical science liaison team building and health economics and outcomes research. He has also served as a member of the Advisory Committees for Reproductive Health Drugs and Drug Safety and Risk Management for the FDA’s Center for Drug Evaluation and Research. Dr. Gut was appointed the Chief Medical Officer of Versartis, Inc. in September 2017 and received his Doctor of Medicine degree from the Medical University of Lublin, and his Doctorate degree from Lublin Institute of Medicine, Poland. He attended numerous postgraduate programs at Wharton, Stanford and Harvard Business School.
Harry Murtaugh is the Executive Director of Sales Operations at Ashfield Healthcare, a Contract Services Organization focused on providing its clients with creative, innovative and tailored solutions. In this role, Harry works with emerging, small and mid-sized Pharmaceutical and Biotechnology clients to help provide them with a best-in-class commercial infrastructure. This will center around the areas of data acquisition, data analysis, data warehousing, sales force automation, fleet management, PDMA sample compliance and accountability, state and aggregate spend reporting, samples and literature fulfillment, production and ad-hoc report design and delivery, incentive compensation design and tracking, field communications, sales force sizing and structure, territory alignments and physician targeting and call planning. He is also responsible for establishing strategic partnerships with other Pharmaceutical and Biotechnology service providers that specialize in the functional areas listed above.
Harry brings over 30 years of experience in the pharmaceutical industry, the past 13 of which having been spent running and building Sales Operations departments in organizations of various sizes. Most recently he was Director, Sales Operations and Training at Promius Pharma, L.L.C. At Promius Pharma, he was directly responsible for the development and implementation of all Sales Operations infrastructure.
Prior to joining Promius, Harry held the positions of Director, Sales Reporting and Analytics at King Pharmaceuticals; Principal Consultant at Aecio Technologies (HighPoint Solutions); Director, Market Planning and Sales Operations at Sankyo Pharma; Regional Sales Director at Sankyo Pharma; and various roles at Novo Nordisk Pharmaceuticals including
Harry is a past Board Member of the PDMA Alliance and was the 2011 Chairman of the PDMA Alliance Sharing Conference held in San Antonio, Texas in September of last year.
Aaron Galaznik is Sr. Director, Real World Data and Analytics at Pfizer Inc. He received his AB in Biology from Harvard University, his MD from Weill Medical College of Cornell University, and his MBA in Healthcare Management from the Wharton School. Currently he is responsible for HEOR evidence for the US Chantix team, including prospective observational studies, retrospective database analyses on impacts of coverage policies, and economic model development, as well as training and roll-out of tools and study findings to field-based medical account teams. He also works closely with account teams to identify strategic opportunities for collaboration with key Payors in the US market. Prior to this role, he served in Market Analytics for Worldwide Commercial Development, where he provided market assessment, product lifecycle opportunity evaluation, segmentation and forecasting support for Celebrex, as well as pre-launch evaluations of pipeline compounds and in-licensing opportunities in pain and inflammation. Prior to coming to Pfizer in 2007 he was at King Pharmaceuticals in Strategic Marketing Research, where he oversaw assessments of promotional activities, product segmentation and positioning, and lifecycle opportunities for Altace as well as market opportunity assessments for pipeline compounds in CV/Metabolics, autoinjector devices, and wound healing. He has also authored and co-authored publications and posters on the impacts of managed care policies on drug utilization and persistence.
Jerry Fjermestad is a professor in the School of Management at NJIT. He received his B.A. in chemistry from Pacific Lutheran University, an MS in operations research from Polytechnic-NYU, and an M.B.A. and Ph.D. from Rutgers University in management information systems. Jerry’s current research deals with business intelligence and data warehousing and on computer-mediated-communications and leadership, electronic customer relationship management, and information personalization, privacy and security. He has co-edited eleven special issues in various IS journals including the International Journal of Electronic Commerce, Electronic Markets, and Group Decision and Negotiation. Jerry’s publications include one edited book on CRM and over a hundred scholarly papers in a number of journals and proceedings such as Communications of the ACM, Decision Support Systems, Journal of Management Information Systems, and Information and Management. He serves on the editorial board for several journals and organizations, including Journal of Information Science and Technology, the International Journal of Electronic Collaboration, and the International Journal of Information Security and privacy.